*Refresh the page if the below document does not appear.
NPPA fixes the cost of Sun Pharma's Amoxycillin, Potassium Clavulanate Oral drug
The NPPA (National Pharmaceutical Pricing Authority) fixed the retail price of antibiotic fixed dose combination drug, Amoxycillin and Potassium Clavulanate Oral Suspension IP, produced and marketed by Sun Pharmaceutical Ltd. at ₹168.43 Per Vial (50ml).
Aurobindo Pharma signs agreement with IMT Hyderabad
Drugmakers Aurobindo pharma has signed an exclusive MoU with IMT Hyderabad to offer custom designed Certified Leadership Program (CLP) termed ‘Auro Astra’ for its employees.
Pharmaceutical firms fight fake drugs with smart supply chains
Drug counterfeiting and supply chain disruptions are common problems arising from poor post-pandemic market conditions. Thus, by 2023 almost 75% of manufacturers will invest in intelligent supply chain solutions to inculcate resilience and prevent disruptions due to health emergencies.
Orchid Pharma's board approves QIP programme to raise funds from institutions
On Thursday, Orchid Pharmaceuticals announced during its regulatory filing that its board has approved raising ₹500 crores from the Qualified Institutional Placement (QIP) program from its institutional investors.
Alembic Pharma gets USFDA nod for Diclofenac Sodium Topical Solution
The USFDA has given final approval to Alembic Pharm’s ANDA (Abbreviated New Drug Application), Diclofenac Sodium Topical Solution USP, 2% w/w which is indicated for the treatment of pain of osteoarthritis of knees.
Akums, Leiutis Pharma, and Biophore India partners to research a range of products
Akums Pharma announced that they have collaborated with Leiutis Pharmaceuticals LLP and Biophore India Pharma for the research and development of a range of products focusing on various therapy areas like CNS disorders, pain management, and hormonal disorders.
USFDA approves Rigel Pharma's treatment for a special condition of Myeloid Leukemia
Rigel Pharma declared on Thursday that the US health authority has approved its drug (under the brand name Rezlidhia) for the treatment of acute myeloid leukemia in patients with a special condition of susceptible genetic mutation.
